ARTV vs CRL · $37.3M cap vs rev $2.00B
Artiva Biotherapeutics, Inc. Common Stock (ARTV) versus Charles River Laboratories (CRL) — a side-by-side from cached financials, not a winner call.
Artiva Biotherapeutics, Inc. Common Stock (ARTV) is a biotechnology company listed on US.
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
Latest reported ARTV revenue for 2025-12-31 was $0. Net income was -$83.9M. Revenue was down 100.0% from 2024-12-31 to 2025-12-31. ARTV currently screens at market cap $37.3M.
Latest reported CRL revenue for 2026-06-27 was $2.00B. Net income was -$16.3M. CRL currently screens at market cap $7.78B.
ARTV currently screens at market cap $37.3M. CRL currently screens at market cap $7.78B.
Not investment advice. Open the ARTV and CRL stock pages for the full models.
Not investment advice.